Abstract:Abstract MAPK7/ERK5 (extracellular-signal-regulated kinase 5) is the effector kinase of a canonical three-tiered MAPK (mitogen activated protein kinase) signalling cascade comprising MEK (MAPK/ERK kinase) 5, MEKK(MEK kinase) 2/3 and ERK5 itself(1). Under normal physiological conditions, MEK5 and ERK5 are ubiquitously expressed and are activated by growth factors and cellular stresses to perform roles in blood vessel, cardiac and muscle development(2). Although the MAPK7-axis is the least well studied of the MAPK-signaling pathways, evidence suggests that it plays a role in the pathology of cancer, in particular; breast cancer progression, prostate cancer bone metastases and hepatocellular carcinoma(3-5). Array-based comparative genomic hybridisation profiling (aCGH) of non-small cell lung cancer (NSCLC) patient tumor samples initially identified MAPK7 gene amplification as a novel genetic event. To further explore the role of MAPK7 in human cancer, we assessed the true incidence of MAPK7 gene amplification using fluorescence in situ hybridization (FISH) analysis in a cohort of 80 NSCLC and 95 squamous esophageal cancers (sqEC). High level MAPK7 gene amplification was detected in 4% (3/80) of NSCLC (enriched to 6% (3/49) in squamous cell carcinoma) and 2% (2/95) of sqEC. Immunohistochemical (IHC) analysis of the same tissue samples revealed a good correlation of MAPK7 gene amplification and high level protein expression but importantly, also identified a high prevalence of IHC ‘3+’ MAPK7 protein expression (20% - 15/74 NSCLC) in the absence of gene amplification. To validate MAPK7 as an oncogenic driver of tumor cell proliferation, we performed in vitro siRNA knockdown of MAPK7 in amplified and non-amplified tumor cell lines. Potent anti-proliferative effects were only observed when MAPK7 protein expression was ablated in MAPK7-amplified lines (eg. KYSE30). To support drug discovery efforts, a novel MEK5/MAPK7 co-transfected HEK293 cell line was developed and used for routine cell-based pharmacodynamic screening. In parallel, reverse-phase protein arrays (RPPA) were used to identify novel candidate downstream pharmacodynamic biomarkers of MAPK7 kinase inhibition in tumor cells (pMEF2A and pMEF2C). Finally, a novel MAPK7-amplified esophageal xenograft model was established and used to demonstrate direct pharmacodynamic modulation of pMAPK7 using a commercially available tool compound (XMD8-92). Taken together, these data highlight a broader role for dysregulated MAPK7 in driving tumorigenesis within niche populations of highly prevalent tumor types, and describe current efforts in establishing a robust drug discovery screening cascade. 1. Zhou, G. (1995) J. Biol. Chem. 270, 12665-12669 2. Lochhead PA. (2012) Biochem Soc Trans. 40(1):251-6. 3. Song, H. (2004) Oncogene 23, 8301-8309 4. Mehta, P.B. (2003) Oncogene 22, 1381-1389 5. Zen, K. (2009) Genes Chromosomes Cancer 48,109-120 Citation Format: Paul R. Gavine, Mei Wang, Dehua Yu, Eva Hu, Chunlei Huang, Jenny Xia, Xinying Su, Joan Fan, Tianwei Zhang, Qingqing Ye, Li Zheng, Liang Xie, Luna Han, Guanshan Zhu, Ziliang Qian, Qingquan Luo, Yingyong Hou, Qunsheng Ji. Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2923. doi:10.1158/1538-7445.AM2014-2923

The MAP3K7 gene: further delineation of clinical characteristics and genotype/phenotype correlations

Compound heterozygous mutations in TTC7A cause familial multiple intestinal atresias and severe combined immunodeficiency.

Heterozygous MAP3K20 variants cause ectodermal dysplasia, craniosynostosis, sensorineural hearing loss, and limb anomalies

Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

Recurrent p.H119Y variant in MAP2K1 expands the phenotypic spectrum of MAP2K1‐related RASopathy

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution

Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease

Phenotype correlations with pathogenic DNA variants in the gene

Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish

Simplex cerebral cavernous malformations with MAP3K3 mutation have distinct clinical characteristics

Syndromic craniosynostosis caused by a novel missense variant in MAP4K4: Expanding the genotype–phenotype relationship in RASopathies

Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy

Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations

Whole Exome and Target Sequencing Identifies MAP2K5 As Novel Susceptibility Gene for Familial Non-Medullary Thyroid Carcinoma

Abstract 2923: Identification and Validation of Dysregulated MAPK7 (ERK5) As a Novel Oncogenic Target in Squamous Cell Lung and Esophageal Carcinoma

Comprehensive EHMT1 variants analysis broadens genotype-phenotype associations and molecular mechanisms in Kleefstra syndrome

Mutations in KEOPS-complex Genes Cause Nephrotic Syndrome with Primary Microcephaly

Cardiac Phenotype and Gene Mutations in RASopathies

An Unexpected Finding of a PTPN11 Germline Mutation in a Patient With a Melanocytic Lesion With a Somatic MAP2K1 Mutation. Coincidence or Not?

Phenotype Correlations With Pathogenic DNA Variants in the MUTYH Gene: A Review of Over 2000 Cases